Structure–activity and structure–metabolism relationships of HIV protease inhibitors containing the 3-hydroxy-2-methylbenzoyl-allophenylnorstatine structure
- 2 January 2004
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 12 (1) , 281-293
- https://doi.org/10.1016/j.bmc.2003.10.037
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Reduction of Peptide Character of HIV Protease Inhibitors That Exhibit Nanomolar Potency against Multidrug Resistant HIV-1 StrainsJournal of Medicinal Chemistry, 2003
- Lopinavir/ritonavir (ABT-378/r)Expert Opinion on Pharmacotherapy, 2002
- A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active SiteJournal of Virology, 2002
- JE-2147: A dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1Proceedings of the National Academy of Sciences, 1999
- Structure−Activity Relationship of Small-Sized HIV Protease Inhibitors Containing AllophenylnorstatineJournal of Medicinal Chemistry, 1999
- Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 ProteaseJournal of Medicinal Chemistry, 1997
- Current antiretroviral therapy: an overviewQuality of Life Research, 1997
- Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatineStructure, 1995
- In vivo emergence of HIV-1 variants resistant to multiple protease inhibitorsNature, 1995
- Synthesis and structure-activity relations of bestatin analogs, inhibitors of aminopeptidase BJournal of Medicinal Chemistry, 1977